National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
Search
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Clinical Trials (PDQ®)
Patient VersionHealth Professional Version
Last Modified: 4/12/2007     First Published: 9/25/2004  
Page Options
Print This Page  Print This Page
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

NIH Calendar of Events

Español
NCI Highlights
Imiquimod May Help to Prevent Vulvar Cancer

Sorafenib Increases Risk of High Blood Pressure

Past Highlights
HPV Vaccines for Cervical Cancer
BreastCancerTrials.org
Phase II Study of Fluorouracil, Cisplatin, and Radiotherapy in Patients With Previously Untreated Stage IIB-IVB Nasopharyngeal Cancer

Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outcomes
Outline
Trial Contact Information
Registry Information

Alternate Title

Fluorouracil, Cisplatin, and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Nasopharyngeal Cancer

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

Phase II


Treatment


Closed


18 to 70


Other


AICHI-UHA-HN03-01
NCT00093665

Objectives

Primary

  1. Determine progression-free survival of patients with previously untreated stage IIB-IVB nasopharyngeal cancer treated with fluorouracil, cisplatin, and radiotherapy.

Secondary

  1. Determine overall survival and response rate in patients treated with this regimen.
  2. Determine compliance to this regimen in these patients.
  3. Determine the toxicity of this regimen in these patients.

Entry Criteria

Disease Characteristics:

  • Histologically confirmed nasopharyngeal cancer (NPC)
    • Type I-III disease by WHO classification
    • Stage IIB-IVB disease by TNM classification with no distant metastases by chest x-ray, liver ultrasonography or CT scan, and bone scintigraphy
      • Lymph node metastases evaluated by CT scan, MRI, and palpation
    • Progression range of primary lesion evaluated by MRI and pharyngeal fiberoptic endoscopy


Prior/Concurrent Therapy:

Biologic therapy

  • No prior biologic therapy for NPC

Chemotherapy

  • No prior systemic chemotherapy for NPC

Endocrine therapy

  • Not specified

Radiotherapy

  • Not specified

Surgery

  • Not specified

Patient Characteristics:

Age

  • 18 to 70

Performance status

  • ECOG 0-2

Life expectancy

  • Not specified

Hematopoietic

  • WBC > 3,500/mm3
  • Platelet count > 100,000/mm3

Hepatic

  • No severe hepatic dysfunction

Renal

  • Creatinine clearance > 60 mL/min
  • No severe renal dysfunction

Cardiovascular

  • No severe cardiac dysfunction

Pulmonary

  • No severe pulmonary dysfunction

Other

  • No other active cancer

Expected Enrollment

90

A total of 90 patients will be accrued for this study within 2 years.

Outcomes

Primary Outcome(s)

Progression-free survival at 3 years

Secondary Outcome(s)

Overall survival
Response rate
Treatment completion rate
Incidence of adverse effects

Outline

This is a multicenter study.

Patients receive chemotherapy comprising fluorouracil IV continuously on days 1-5 and cisplatin IV continuously on days 6-7. Beginning 2-3 days after the completion of chemotherapy, patients undergo radiotherapy once daily, 5 days a week, for 4 weeks. With 2-3 days between each course, patients receive a second course of chemotherapy, undergo a second course of radiotherapy, and then receive a third course of chemotherapy. Treatment continues in the absence of unacceptable toxicity or disease progression.

Patients are followed for 3 years.

Trial Contact Information

Trial Lead Organizations

Aichi Cancer Center

Nobukazu Fuwa, Protocol chair
Ph: 81-52-762-6111

Registry Information
Official Title A Phase II Study Of Alternating Chemoradiotherapy For Nasopharyngeal Cancer Using Cisplatin And 5-Fluorouracil
Trial Start Date 2003-11-01
Registered in ClinicalTrials.gov NCT00093665
Date Submitted to PDQ 2004-08-24
Information Last Verified 2006-10-01

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.

Back to TopBack to Top

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov